- Research article
- Open Access
- Open Peer Review
MicroRNA-34a is a tumor suppressor in choriocarcinoma via regulation of Delta-like1
© Pang et al.; licensee BioMed Central Ltd. 2013
- Received: 19 July 2012
- Accepted: 10 January 2013
- Published: 18 January 2013
Choriocarcinoma is a gestational trophoblastic tumor which causes high mortality if left untreated. MicroRNAs (miRNAs) are small non protein-coding RNAs which inhibit target gene expression. The role of miRNAs in choriocarcinoma, however, is not well understood. In this study, we examined the effect of miR-34a in choriocarcinoma.
MiR-34a was either inhibited or ectopically expressed transiently in two choriocarcinoma cell lines (BeWo and JEG-3) respectively. Its actions on cell invasion, proliferation and colony formation at low cell density were examined. The miR-34a putative target Notch ligand Delta-like 1 (DLL1) was identified by adoption of different approaches including: in-silico analysis, functional luciferase assay and western blotting. Real-time quantitative polymerase chain reaction was used to quantify changes in the expression of matrix proteinase in the treated cells. To nullify the effect of miR-34a ectopic expression, we activated Notch signaling through force-expression of the Notch intracellular domain in the miR-34a force-expressed cells. In addition, we studied the importance of DLL1 in BeWo cell invasion through ligand stimulation and antibody inhibition. Furthermore, the induction in tumor formation of miR-34a-inhibited BeWo cells in SCID mice was investigated.
Transient miR-34a force-expression significantly suppressed cell proliferation and invasion in BeWo and JEG-3 cells. In silicon miRNA target prediction, luciferase functional assays and Western blotting analysis demonstrated that miR-34a regulated DLL1 expression in both cell lines. Although force-expression of miR-34a suppressed the expression of DLL1 and NOTCH1, the extent of suppression was higher in DLL1 than NOTCH1 in both cell lines. MiR-34a-mediated DLL1 suppression led to reduced matrix metallopeptidase 9 and urokinase-type plasminogen activator expression. The effect of miR-34a on cell invasion was partially nullified by Notch signaling activation. DLL1 ligand stimulated while anti-DLL1 antibody treatment suppressed cell invasion. Mice inoculated with BeWo cells transfected with miR-34a inhibitor had significantly larger xenografts and stronger DLL1 expression than those with cells transfected with the control inhibitor.
MiR-34a reduced cell proliferation and invasiveness, at least, partially through its inhibitory effect on DLL1.
Choriocarcinoma is a highly malignant trophoblastic tumor characterized by abnormal trophoblastic hyperplasia and anaplasia. It can be derived either from a normal or pathological pregnancy like molar pregnancies, induced/spontaneous abortions, ectopic pregnancies and preterm deliveries . Although choriocarcinoma is a rare disease, if left untreated, can spread rapidly and has a mortality rate of nearly 100% . During organ transplantation, dissemination of choriocarcinoma cells from donors to recipients can lead to quick death of the recipients . Our knowledge on choriocarcinoma is very limited due to its rarity and lack of proper controls in studies. Besides, heterogeneous causes of the disease make study of the disease much more complicated; cytogenetic analyses indicate that nearly all chromosomes can be affected and no consistent abnormality has been identified in choriocarcinoma .
MicroRNAs (miRNAs) are small untranslated RNAs that inhibit expression of target genes through translational inhibition or transcriptional silencing . Bioinformatics analysis predicts that 30% of all the protein-coding genes are targets of miRNAs . MiRNAs is involved in various physiological processes while aberrant miRNA expressions are usually pathological. Previously, only the roles of miR-141 and miR-199b in choriocarcinoma were reported [7, 8]. The significance of other miRNAs in choriocarcinoma is not known.
The miR-34 family members share high sequence homology . Among these, miR-34a is one of the earliest known miRNA tumor suppressor and is directly transactivated by p53 [10, 11]. In this study, we used BeWo and JEG-3 cells as model to examine the role of miR-34a as a tumor-suppressor in choriocarcinoma. These 2 cell lines are widely used for the study of trophoblast physiology and trophoblastic cancer. Hence, we used gain/loss of function approach and demonstrated that miR-34a affected proliferation, colony-formation and invasion of choriocarcinoma cells in vitro and the tumor formation capability in vivo.
Notch signaling is a short range communication transducer system which is important in many physiological and pathological conditions  and is highly conserved. There are 4 Notch receptors (Notch 1–4) and 5 Notch ligands (DLL1, 3, 4 and Jagged1, 2) and belongs to the type I membrane-bound proteins. Upon ligand binding, the intracellular domain of the Notch receptor (NCID) is cleaved and translocated into the nucleus, where it acts as a transcriptional factor for target gene activation . Bioinformatics analyses suggest that the Notch ligand, delta-like one (DLL1) is a target of miR-34a. This was further confirmed in the present study by the 3’-untranslated region (UTR) luciferase functional assay. The data also demonstrated that DLL1 and Notch signaling mediated the action of miR-34a in cell invasion.
The BeWo cells and JEG-3 cells (American Type Culture Collection, Manassas, VA) were cultured respectively in F12K medium or DMEM medium, (Invitrogen, Carlsad, CA) supplemented with 10% fetal bovine serum (FBS), 50 U/ml of penicillin and 50 μg/ml of streptomycin (Invitrogen). For force-expression of miR-34a, 1 × 105 cells were seeded in 12-well culture plates 1 day before transfection either with 50 nM of precursor of miR-34a (pre-miR-34a) or pre-miR-Scramble (Negative Control #1, Ambion, Austin, TX) by Lipofectamine 2000 (Invitrogen). For activation of Notch signaling, a Notch NCID expression plasmid (pCDNA6-Notch NCID, a kind gift from Prof. Jon Aster, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA) was used. In control experiments, the cells were transfected with an empty vector (pCDNA6).
Cell proliferation was estimated by the CyQuant® cell proliferation assay (Invitrogen) according to the manufacturer’s protocol. Fluorescence signal with excitation at 485 nm and emission at 530 nm was measured by a microplate reader (Tecan Group Ltd, Männedorf, Switzerland).
We used the BD Matrigel Invasion Chamber (8-μm pore size; BD Biosciences, Franklin Lakes, NJ) to quantify cell invasion. The transfected cells in FBS-free culture medium were seeded onto the upper chamber while the lower chamber was filled with normal FBS-containing medium. For DLL1 stimulation, 2.5 μg of recombinant DLL1 (R&D systems, Minneapolis, MN) was added to the upper chamber. In the control experiment, the same volume of DMSO was added to the cells. For antibody inhibition, 5 μg of polyclonal anti-DLL1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was added to the upper chamber during seeding, and fresh antibody was added every 24 hours. After 48 hours, the cells remained in the upper chamber were removed by cotton swabs, whilst those that had invaded through the matrix between the two chambers were visualized by staining with 0.1% of crystal violet (Sigma-Aldrich, St Louis, MO). To quantify the invasion result, the dye was dissolved in 10% acetic acid and the absorbance was measured by a microplate reader. Parallel experiments on cell proliferation were performed to estimate the effect of cell proliferation on the results of cell invasion.
Total RNA extraction, reverse transcription and quantitative real-time quantitative PCRs (RT-qPCR)
Total RNA was prepared by using the mirVanaTM miRNA Isolation Kit (Ambion) according to the manufacturer’s protocol. For assaying mRNA, first-strand cDNA was synthesized by the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) and the target gene expression was quantified by the TaqMan® Gene Expression Assays (Applied Biosystems) using an Applied Biosystems 7500 Detection system (Applied Biosystems). The expression of mRNA was determined from the threshold cycle (Ct), and the relative expression levels were calculated by the 2-ΔΔCt method . The relative expression levels were normalized with the expression of 18S mRNA. For measuring miRNAs, the first-strand cDNA was synthesized by the TaqMan® MicroRNA Reverse Transcription kit (Applied Biosystems) and the miRNA expression was quantified by the TaqMan® MicroRNA assay (Applied Biosystems). The relative expression of miR-34a was calculated as the above and the levels were normalized with the expression of the small RNA RNU6B.
3’UTR functional luciferase assays
Oligonucleotides were synthesized according to the nucleotide sequence of potential miR-34a binding regions identified by TargetScan5.2 on DLL1 (355–361 of DLL1 3’UTR, NCBI reference sequence: NM_005618.3). Specific primers were purchased from Invitrogen (Forward: 5’-TCCTCGAGAA TTAGAAACAC AAACACTGCC TGCGGCCGCT G-3’ and Reverse: 5’-CAGCGGCCGC AGGCAGTGTT TGTGTTTCTA ATTCTCGAGG A-3’). The DNA fragment was cloned into the Xho I and Not I sites of the pSiCheck™-2vector (Promega, Madison, WI). The vector was transfected with either pre-miR-34a or pre-Scramble into the cells (Ambion). At 48-hour post-transfection, the cells were lysed and the luciferase activities in the lysate were measured by the Dual Luciferase Reporter Assay System (Promega). The effect of the miRNA was measured by the activity of the Renilla luciferase normalized to that of the firefly luciferase. To test the specificity of the interaction between miR-34a and 3’UTR of DLL1, the miR-34a seed binding region on the 3’UTR of DLL1 was mutated. The mutant construct was generated with specific primers (Forward: 5’-TCCTCGAGAA TTAGAAACAC AAAGAGTACT TGCGGCCGCT G-3’ and Reverse: 5’-CAGCGGCCGC AAGTACTCTT TGTGTTTCTA ATTCTCGAGG A-3’; underlined regions denote the mutated sequences) and cloned into the pSiCheck™-2vector as described above.
Colony formation assay
BeWo and JEG-3 cells transfected with pre-miR-34a or pre-Scramble were seeded at a density of 20 cells/cm2 in normal culture medium as stated as the above and allowed to grow for 2 weeks. The colonies were then stained with 0.1% crystal violet (Sigma-Aldrich), washed with PBS and their number was counted. Images of the colonies were scanned with a gel documentation system (AlphaImager® HP, Alpha Innotech Corporation, San Leandro, CA).
In vivotumorigenicity assay
The study protocol was approved by the Committee on the Use of Live Animals in Teaching and Research at the University of Hong Kong. BeWo cells were transfected either with 50 nM of miR-34a miRCURY LNA™ knockdown probe or control (Exiqon, Vedbaek, Denmark). The transfected BeWo cells (1 × 106) were resuspended in 100 μl of PBS, mixed with 100 μl of matrigel (BD Biosciences), and injected subcutaneously into both sides of the posterior flanks of 4- to 6-week-old female B-17/Icr-scid (SCID) mice. The animals were sacrificed after 4 weeks. Four mice were used in each experiment and the experiment was repeated for 5 times independently.
Western blot analysis
Cell lysates were prepared as described . The protein expression of DLL1, NOTCH1 and β-actin were detected using specific anti-DLL1 (Santa Cruz, sc-9102), anti-NOTCH1 (Santa Cruz, sc-6014) and anti-β-actin antibodies (Santa Cruz, sc-47778). The denatured protein samples were resolved on a 8% denaturing SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked with Tris-buffered saline containing 5% nonfat milk and 0.5% Tween 20 (blocking buffer) at room temperature for 1 hour. Hybridization was performed at 4°C overnight (1oAb 1:1000 for DLL1 and NOTCH1, 1:10000 for β-actin), followed by extensive washing and incubation with appropriate horseradish peroxidase-conjugated secondary antibody (1:2500) in blocking buffer for 1 hour at room temperature. The protein bands were detected by chemiluminescence detection.
Tissues preparation and immunohistochemistry were performed as described . Briefly, antigen retrieval was performed by heating the sections in 1X target antigen retrieval solution (Dako, Glostrup, Denmark). Non-specific binding was blocked by incubating the tissue sections in PBS containing 5% serum (Sigma-Aldrich) and 0.1% Tween 20. DLL1 immunoreactivities were detected by successive incubation with specific antibody against DLL1 (Santa Cruz), biotinylated polyclonal rabbit anti-goat IgG (Dako) and Strep ABComplex/Horseradish Peroxidase HRP (Vector Laboratories, Burlingame, CA). Signal was visualized with 3,3’-diaminobenzidine (Dako).
Each experiment was repeated independently for at least 3 times. All the values were reported as means ± SD. Differences between the treatment and the control groups were analyzed by Kruskal-Wallis test. p < 0.05 was considered as statistically significant.
MiR-34a reduces proliferation and invasion of choriocarcinoma cell lines
Next, we assessed the action of miR-34a on cell invasion. The miR-34a force-expressed cells were allowed to invade a matrigel membrane for 48 hours. It was found that the invasiveness of the miR-34a force-expressed choriocarcinoma cells was significantly decreased when compared with the control group (Figure 1C).
Delta-like one (DLL1) is a target of miR-34a in choriocarcinoma cells
NOTCH1 is a known miR-34a targeted gene in choriocarcinoma cells . We compared the action of miR-34a on the protein expression of NOTCH1 and DLL1. It was found that miR-34a force-expression decreased the level of DLL1 to a greater extent than that of NOTCH1 in both BeWo and JEG-3 cells (Figure 2B). Therefore, we focused our study on DLL1.
We further examined whether there is a direct interaction between miR-34a and DLL1. We constructed a luciferase reporter carrying the 3’UTR of DLL1 and transfected the reporter with either the pre-miR-34a or scramble miRNA precursor into BeWo cells. Force-expression of miR-34a reduced the luciferase reporter activity by more than 50% (p < 0.05, Figure 2C). To determine the specificity of the interaction, another reporter vector carrying a mutation at the putative seed binding sequence was constructed. Force-expression of miR-34a had no significant effect on the reporter activities of the mutant construct, confirming the specificity of the action of miR-34a on DLL1.
To study the mechanism of action of miR-34a on DLL1 expression, we determined the mRNA expression of DLL1 upon miR-34a force-expression, RT-qPCR revealed that the treatment and the control groups had similar levels of the DLL1 mRNA (Figure 2D). The observation indicated that miR-34a regulated DLL1 expression in choriocarcinoma cells through translational inhibition. Similarly, the expression of NOTCH1 mRNA was not affected by miR-34a force-expression. To confirm that the action of miR-34a on DLL1 modulated Notch signaling, we examined the expression of the Notch signaling target gene Hairy Enhancer of Split-1 protein (Hes-1) and found that it was reduced upon force-expression of miR-34a in both cell lines (Figure 2E).
MiR-34a regulates invasion of BeWo cells through the Notch signaling pathway
MiR-34a knockdown enhances tumor growth in vivo
MiR-34 family members were first identified as tumor suppressors [10, 11] and are associated with a variety of tumors . However, their roles in pathogenesis are poorly understood. Recently, their family members were shown to regulate neurite outgrowth, morphology and functions , late steps of spermatogenesis  and modulate the first cleavage of mouse preimplantation embryos . In this study, we explored the action of miR-34a in choriocarcinoma cell lines.
We observed a delayed action of miR-34a force-expression on proliferation, in which a significant inhibition was detected only at 168-hour post-transfection whereas a decrease in DLL1 protein level occurred at 72-hour post-transfection. Similar finding was reported in glioma stem cells . DLL1 is a transmembrane ligand of the Notch signaling pathway. The delayed action could be due to the need of adequate physical contact between adjacent cells for sufficient activation of Notch signaling before an effect on proliferation could be observed, and the contact was inadequate in the early part of the experiment when the cell density was low. The explanation is consistent with a previous report demonstrating that another Notch-ligand JAG1 affects proliferation only when the cell density is above certain density .
p53 has a key role in inducing apoptosis and exerts its tumor-suppressive effect partially through miR-34a . In many solid tumors, p53 malfunction is a consequence of gene mutation. However, direct sequencing cannot detect mutation in p53 cDNA of gestational trophoblastic disease [23, 24]. In fact, p53 is highly expressed in choriocarcinoma  and is associated with a more aggressive behavior . This is in contrast to many other cells, which undergo programmed cell death when the level of p53 is high. It is possible that there is a malfunction of the p53 effectors in the choriocarcinoma enabling the cells to survive under such condition. Suppression of the apoptosis-stimulating proteins of p53 (ASPP1), a member of the p53 transcriptional complex, through promoter hypermethylation in choriocarcinoma cell lines supports this possibility . In fact, force-expression of ASPP1 in choriocarcinoma cell line has profound effects on reducing tumorigenecity . The present study suggests that miR-34a is another component of the p53 network important in tumor suppression.
Metastasis is a major cause of cancer deaths while tumor invasion is an early marker of metastasis. Thus, understanding of tumor invasion is of great importance. MiR-34a inhibits invasion in a number of tumors including prostate cancer , colon cancer , cervical cancer  and hepatocellular cancer . Our findings support these observations and further show that miR-34a regulates invasion through DLL1 leading eventually to reduction in the expression of the matrix degrading enzymes.
DLL1 is a target of miR-34a in medulloblastoma . As the targets of miRNA are cell context-dependent , a reporter assay was conducted to confirm the direct interaction of miR-34a with DLL1 in choriocarcinoma. In fact, several Notch receptors and ligands have been demonstrated to be targets of miR-34a. These include DLL1 (; this study), JAG1[15, 33], NOTCH1 [15, 34], NOTCH2 . In this study, we also demonstrated that miR-34a inhibits NOTCH1 expression by translational inhibition in choriocarcinoma cells.
Notch signaling components are expressed in the trophoblast during normal pregnancy . Apart from choriocarcinoma cell lines , there is no study on Notch signaling in primary choriocarcinoma tissues. In other cancers, aberrant expression and activation of Notch signaling are associated with changes in cell invasion . In this study, we found that DLL1/Notch signaling mediated the action of miR-34a; activation of the Notch signaling through NCID transfection nullified the action of force-expression of miR-34a on suppressing the invasion of BeWo cells. As there are at least 3 miR-34a-targeted Notch components, DLL1, NOTCH1 and JAG1 in choriocarcinoma cells, the observed tumor suppressive effect of miR-34a and its action on Hes-1 could be a summation effect of miR-34a on these Notch targets.
Our data showed that miR-34a force-expression suppressed invasion by reducing the expression of MMP-9 and uPA. Both enzymes are regulated by AP-1 transcription factor complex [29, 37]. Choriocarcinomas have a strong expression of members of the AP-1 family including, c-Jun, Jun D and Fra1 . MiR-34a may regulate AP-1 complex through two pathways. The first pathway is the direct action of miRNA on its target, Fra-1 , which is an integral part of AP-1. One of the downstream effectors of Notch signaling is AP-1. Therefore, the second pathway is indirectly through Notch signaling. As stated above, several components of the Notch signaling are target of the miR-34 family members [15, 31, 33, 34]. In this study, Notch signaling activation nearly fully nullified the effect of miR-34a indicating the Notch pathway being the major miR-34a target for controlling cell invasion in our model.
Notch signaling plays an important role in cancer. It is essential for cell survival and has anti-apoptotic roles [39–41]. Some tumor cells termed cancer stem cells possess stem-cell-like properties and exhibit enhanced chemoresistance and malignancy capabilities . The Notch, Hedgehog and Wnt signaling pathways are the strongest stem cell promoting pathways keeping the stem cells in an undifferentiated state. It has been suggested that treatment targeting these pathways can inhibit tumor relapse and improve overall cancer survival [43, 44]. For example, activation of the Notch signaling pathway can determine cancer cell stemness and tumorigenicity in certain cases [31, 45]. Currently, there are evidences indicating that miR-34a is at least a suppressor of the Notch [15, 33] and the Wnt signaling pathway , and that miR-34a force-expression negatively affects tumor-propagating cells through inhibiting DLL1 in medulloblastoma . Our study provides further evidence that miR-34a reduces tumorigenicity through DLL1 but whether miR-34a regulates cancer stem cells stemness in choriocarcinoma remains to be determined.
In summary, this study demonstrates that miR-34a is a tumor suppressive miRNA in choriocarcinoma cells. The miRNA exerts its biological activities through regulation of the Notch ligand DLL1. It is possible that miR-34a can be used as a therapeutic target for treating choriocarcinoma in the future.
The work is supported by a GRF grant from the Research Grant Council (Ref: 780308), Hong Kong.
- Cheung AN, Zhang HJ, Xue WC, Siu MK: Pathogenesis of choriocarcinoma: clinical, genetic and stem cell perspectives. Future Oncol. 2009, 5 (2): 217-231. 10.2217/147966184.108.40.206.View ArticlePubMedGoogle Scholar
- Lurain JR: Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010, 203 (6): 531-539. 10.1016/j.ajog.2010.06.073.View ArticlePubMedGoogle Scholar
- Marsh JW, Esquivel CO, Makowka L, Todo S, Gordon RD, Tzakis A, Miller C, Morris M, Staschak S, Iwatsuki S, et al: Accidental transplantation of malignant tumor from a donor to multiple recipients. Transplantation. 1987, 44 (3): 449-450. 10.1097/00007890-198709000-00025.View ArticlePubMedPubMed CentralGoogle Scholar
- Hoffner L, Surti U: The genetics of gestational trophoblastic disease: a rare complication of pregnancy. Cancer Genet. 2012, 205 (3): 63-77. 10.1016/j.cancergen.2012.01.004.View ArticlePubMedGoogle Scholar
- Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ: Processing of primary microRNAs by the Microprocessor complex. Nature. 2004, 432 (7014): 231-235. 10.1038/nature03049.View ArticlePubMedGoogle Scholar
- Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E: Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 2005, 120 (1): 21-24. 10.1016/j.cell.2004.12.031.View ArticlePubMedGoogle Scholar
- Morales-Prieto DM, Schleussner E, Markert UR: Reduction in miR-141 is induced by leukemia inhibitory factor and inhibits proliferation in choriocarcinoma cell line JEG-3. Am J Reprod Immunol. 2011, 66 (Suppl 1): 57-62.View ArticlePubMedGoogle Scholar
- Chao A, Tsai CL, Wei PC, Hsueh S, Chao AS, Wang CJ, Tsai CN, Lee YS, Wang TH, Lai CH: Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett. 2010, 291 (1): 99-107. 10.1016/j.canlet.2009.10.005.View ArticlePubMedGoogle Scholar
- Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al: p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007, 17 (15): 1298-1307. 10.1016/j.cub.2007.06.068.View ArticlePubMedGoogle Scholar
- He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA component of the p53 tumour suppressor network. Nature. 2007, 447 (7148): 1130-1134. 10.1038/nature05939.View ArticlePubMedPubMed CentralGoogle Scholar
- Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007, 26 (5): 745-752. 10.1016/j.molcel.2007.05.010.View ArticlePubMedPubMed CentralGoogle Scholar
- Bolos V, Grego-Bessa J, de la Pompa JL: Notch signaling in development and cancer. Endocr Rev. 2007, 28 (3): 339-363. 10.1210/er.2006-0046.View ArticlePubMedGoogle Scholar
- Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner BA: Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc Natl Acad Sci USA. 1999, 96 (12): 6959-6963. 10.1073/pnas.96.12.6959.View ArticlePubMedPubMed CentralGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
- Pang RT, Leung CO, Ye TM, Liu W, Chiu PC, Lam KK, Lee KF, Yeung WS: MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis. 2010, 31 (6): 1037-1044. 10.1093/carcin/bgq066.View ArticlePubMedGoogle Scholar
- Kodithuwakku SP, Pang RT, Ng EH, Cheung AN, Horne AW, Ho PC, Yeung WS, Lee KF: Wnt activation downregulates olfactomedin-1 in Fallopian tubal epithelial cells: a microenvironment predisposed to tubal ectopic pregnancy. Lab Invest. 2012, 92 (2): 256-264. 10.1038/labinvest.2011.148.View ArticlePubMedGoogle Scholar
- Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008, 7 (16): 2591-2600. 10.4161/cc.7.16.6533.View ArticlePubMedGoogle Scholar
- Aranha MM, Santos DM, Sola S, Steer CJ, Rodrigues CM: miR-34a regulates mouse neural stem cell differentiation. PLoS One. 2011, 6 (8): e21396-10.1371/journal.pone.0021396.View ArticlePubMedPubMed CentralGoogle Scholar
- Bouhallier F, Allioli N, Lavial F, Chalmel F, Perrard MH, Durand P, Samarut J, Pain B, Rouault JP: Role of miR-34c microRNA in the late steps of spermatogenesis. RNA. 2010, 16 (4): 720-731. 10.1261/rna.1963810.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu WM, Pang RT, Chiu PC, Wong BP, Lao K, Lee KF, Yeung WS: Sperm-borne microRNA-34c is required for the first cleavage division in mouse. Proc Natl Acad Sci USA. 2012, 109 (2): 490-494. 10.1073/pnas.1110368109.View ArticlePubMedGoogle Scholar
- Hu YY, Zheng MH, Cheng G, Li L, Liang L, Gao F, Wei YN, Fu LA, Han H: Notch signaling contributes to the maintenance of both normal neural stem cells and patient-derived glioma stem cells. BMC Cancer. 2011, 11: 82-10.1186/1471-2407-11-82.View ArticlePubMedPubMed CentralGoogle Scholar
- Simon DP, Giordano TJ, Hammer GD: Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma. Clin Cancer Res. 2012, 18 (9): 2452-2464. 10.1158/1078-0432.CCR-11-2371.View ArticlePubMedGoogle Scholar
- Cheung AN, Srivastava G, Chung LP, Ngan HY, Man TK, Liu YT, Chen WZ, Collins RJ, Wong LC, Ma HK: Expression of the p53 gene in trophoblastic cells in hydatidiform moles and normal human placentas. J Reprod Med. 1994, 39 (3): 223-227.PubMedGoogle Scholar
- Shi YF, Xie X, Zhao CL, Ye DF, Lu SM, Hor JJ, Pao CC: Lack of mutation in tumour-suppressor gene p53 in gestational trophoblastic tumours. Br J Cancer. 1996, 73 (10): 1216-1219. 10.1038/bjc.1996.233.View ArticlePubMedPubMed CentralGoogle Scholar
- Muller-Hocker J, Obernitz N, Johannes A, Lohrs U: P53 gene product and EGF-receptor are highly expressed in placental site trophoblastic tumor. Hum Pathol. 1997, 28 (11): 1302-1306. 10.1016/S0046-8177(97)90206-9.View ArticlePubMedGoogle Scholar
- Fulop V, Mok SC, Genest DR, Gati I, Doszpod J, Berkowitz RS: p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med. 1998, 43 (2): 119-127.PubMedGoogle Scholar
- Mak VC, Lee L, Siu MK, Wong OG, Lu X, Ngan HY, Wong ES, Cheung AN: Downregulation of ASPP1 in gestational trophoblastic disease: correlation with hypermethylation, apoptotic activity and clinical outcome. Mod Pathol. 2011, 24 (4): 522-532. 10.1038/modpathol.2010.216.View ArticlePubMedGoogle Scholar
- Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Deng G, Dahiya R: MicroRNA-34a Modulates c-Myc Transcriptional Complexes to Suppress Malignancy in Human Prostate Cancer Cells. PLoS One. 2012, 7 (1): e29722-10.1371/journal.pone.0029722.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu J, Wu G, Lv L, Ren YF, Zhang XJ, Xue YF, Li G, Lu X, Sun Z, Tang KF: MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis. 2012, 33 (3): 519-528. 10.1093/carcin/bgr304.View ArticlePubMedGoogle Scholar
- Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X: miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009, 275 (1): 44-53. 10.1016/j.canlet.2008.09.035.View ArticlePubMedGoogle Scholar
- de Antonellis P, Medaglia C, Cusanelli E, Andolfo I, Liguori L, De Vita G, Carotenuto M, Bello A, Formiggini F, Galeone A, et al: MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One. 2011, 6 (9): e24584-10.1371/journal.pone.0024584.View ArticlePubMedPubMed CentralGoogle Scholar
- Thomsen S, Azzam G, Kaschula R, Williams LS, Alonso CR: Developmental RNA processing of 3'UTRs in Hox mRNAs as a context-dependent mechanism modulating visibility to microRNAs. Development. 2010, 137 (17): 2951-2960. 10.1242/dev.047324.View ArticlePubMedGoogle Scholar
- Hashimi ST, Fulcher JA, Chang MH, Gov L, Wang S, Lee B: MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood. 2009, 114 (2): 404-414. 10.1182/blood-2008-09-179150.View ArticlePubMedPubMed CentralGoogle Scholar
- Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, et al: MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009, 69 (19): 7569-7576. 10.1158/0008-5472.CAN-09-0529.View ArticlePubMedPubMed CentralGoogle Scholar
- De Falco M, Cobellis L, Giraldi D, Mastrogiacomo A, Perna A, Colacurci N, Miele L, De Luca A: Expression and distribution of notch protein members in human placenta throughout pregnancy. Placenta. 2007, 28 (2–3): 118-126.View ArticlePubMedGoogle Scholar
- Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP: Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res. 2008, 14 (10): 2962-2969. 10.1158/1078-0432.CCR-07-1992.View ArticlePubMedPubMed CentralGoogle Scholar
- Ibanez-Tallon I, Caretti G, Blasi F, Crippa MP: In vivo analysis of the state of the human uPA enhancer following stimulation by TPA. Oncogene. 1999, 18 (18): 2836-2845. 10.1038/sj.onc.1202644.View ArticlePubMedGoogle Scholar
- Briese J, Sudahl S, Schulte HM, Loning T, Bamberger AM: Expression pattern of the activating protein-1 family of transcription factors in gestational trophoblastic lesions. Int J Gynecol Pathol. 2005, 24 (3): 265-270. 10.1097/01.pgp.0000163023.49965.10.View ArticlePubMedGoogle Scholar
- Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B: Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002, 99 (9): 3398-3403. 10.1182/blood.V99.9.3398.View ArticlePubMedGoogle Scholar
- Miele L, Osborne B: Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol. 1999, 181 (3): 393-409. 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6.View ArticlePubMedGoogle Scholar
- Shelly LL, Fuchs C, Miele L: Notch-1 inhibits apoptosis in murine erythroleukemia cells and is necessary for differentiation induced by hybrid polar compounds. J Cell Biochem. 1999, 73 (2): 164-175. 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0.View ArticlePubMedGoogle Scholar
- Tysnes BB: Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia. 2010, 12 (7): 506-515.View ArticlePubMedPubMed CentralGoogle Scholar
- DeSano JT, Xu L: MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J. 2009, 11 (4): 682-692. 10.1208/s12248-009-9147-7.View ArticlePubMedPubMed CentralGoogle Scholar
- Takebe N, Harris PJ, Warren RQ, Ivy SP: Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011, 8 (2): 97-106. 10.1038/nrclinonc.2010.196.View ArticlePubMedGoogle Scholar
- Kim Y, Lin Q, Zelterman D, Yun Z: Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity. Cancer Res. 2009, 69 (24): 9271-9280. 10.1158/0008-5472.CAN-09-1605.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, Kang SE, Cha SY, Ryu JK, Na JM, et al: p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal. 2011, 4 (197): ra71-10.1126/scisignal.2001744.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/25/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.